Abingdon, United Kingdom

Daniel Kwan

USPTO Granted Patents = 2 

Average Co-Inventor Count = 3.7

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2020-2022

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Daniel Kwan

Introduction

Daniel Kwan is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of neurotoxin research, holding a total of 2 patents. His work focuses on the production and application of activated clostridial neurotoxins, which have important implications in medical treatments.

Latest Patents

Kwan's latest patents include innovative methods and compositions related to activated clostridial neurotoxins. One patent details the method of producing an activated clostridial neurotoxin, along with a composition that comprises this neurotoxin. Another patent focuses on chimeric polypeptides, specifically chimeric clostridial neurotoxins where the activation loop has been replaced by one from a different subtype within the same serotype. This work also encompasses methods of producing, activating, and utilizing such neurotoxins, as well as compositions that include them.

Career Highlights

Daniel Kwan is currently associated with Ipsen Biopharm Limited, where he continues to advance his research in neurotoxin applications. His expertise in this specialized field has positioned him as a key figure in the development of therapeutic solutions.

Collaborations

Kwan collaborates with esteemed colleagues such as David Burgin and Stephen Gavin Hackett. Their combined efforts contribute to the innovative research and development of neurotoxin therapies.

Conclusion

Daniel Kwan's work in the field of activated clostridial neurotoxins showcases his dedication to advancing medical science. His patents reflect a commitment to innovation that has the potential to impact treatment methodologies significantly.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…